CD4 Peptide-Polyanion Conjugate for HIV Attachment Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current antiviral treatments for HIV, particularly triple therapies, face challenges with resistance development and adverse effects, necessitating a new approach that targets HIV replication steps other than reverse transcription and proteolysis, and effectively inhibits viral attachment without causing cellular side effects.

Innovation Solution

A conjugated molecule comprising a peptide derived from the CD4 receptor covalently linked to a polyanionic polysaccharide, specifically designed to bind directly to the gp120 protein, inhibiting viral attachment by targeting the CD4-induced epitope and co-receptor binding sites, thereby reducing the risk of resistance emergence.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If triple therapy treatment is used to reduce viral charge, then antiviral efficacy is improved, but adverse effects and resistance development worsen

Engineering Contradiction:

Improveantiviral efficacyVSAvoidadverse effects and resistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the antiviral approach by using separate functional modules: a CD4 peptide module for binding specificity and a polyanion module for inhibitory activity. This segmentation allows each module to be optimized independently, reducing the need for high-dose combination therapies and their associated adverse effects.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention creates a composite molecule by covalently linking a CD4 peptide to a polyanion (such as heparin or heparan sulfate). This composite structure combines the binding affinity of CD4 with the antiviral activity of the polyanion, achieving effective HIV inhibition at lower doses and reducing resistance development.

Inventive Principle:

Principle #40Composite materials

2Reliability

If traditional antiviral drugs are used to target reverse transcription and proteolysis, then viral replication is inhibited, but resistance emergence and poor compliance worsen

Engineering Contradiction:

Improveviral replication inhibitionVSAvoidresistance emergence and compliance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

Instead of inhibiting viral enzymes (reverse transcription and proteolysis), the invention inverts the approach by blocking the initial attachment step. The conjugated molecule binds to gp120 and prevents viral entry into the cell, targeting an earlier stage in the viral lifecycle that is less prone to resistance development.

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If polyanions are used to inhibit HIV attachment, then viral entry is blocked, but anticoagulant effects and cellular side effects worsen

Engineering Contradiction:

ImproveHIV attachment inhibitionVSAvoidanticoagulant effects and cellular side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention applies local quality by attaching the polyanion to a specific CD4 peptide sequence that binds to gp120. This localization ensures the polyanion's antiviral activity is directed specifically at the virus-cell attachment interface, while the peptide component ensures specificity for HIV and reduces off-target effects on cellular processes.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The CD4 peptide acts as an intermediary that mediates between the polyanion and the viral gp120 protein. The peptide provides specific binding to the virus while the polyanion provides the inhibitory effect, allowing the system to achieve antiviral activity without the full anticoagulant effects of free polyanions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The conjugated molecule effectively inhibits HIV attachment to cells, offering a therapeutic advantage by directly targeting the virus rather than the cells, potentially reducing the emergence of resistance and minimizing adverse effects associated with traditional treatments.

Implementation Method 1

bind directly to the gp120 protein, inhibiting viral attachment by targeting the CD4-induced epitope and co-receptor binding sites

Methodology Applied

Scientific EffectViral attachment inhibition:

Implementation Method 2

directly targeting the virus rather than the cells, potentially reducing the emergence of resistance

Methodology Applied

Scientific EffectViral replication inhibition:

Data Source

PatentUS9295730B2Conjugated molecules comprising a peptide derived from the CD4 receptor coupled to a polyanion for the treatment of AIDS

Publication Date: 2016.03.29 INST PASTEUR

AI summary

This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Such a conjugated molecule can be used in antiviral treatment, namely in the treatment of AIDS.